Medical experts push for use of unregistered TB drug

2012-05-28 15:21

Pressure is mounting on the South African government to allow doctors to use a promising but not yet registered antibiotic to treat extensively drug-resistant tuberculosis.

The drug, known as Bedaquiline, forms part of a new generation of highly active antibiotics.

It has been shown, in several local and international clinical trials, to be a cure for drug-resistant TB.

However, it is not yet available in the market for general use because it still has to undergo confirmatory trials.

Confirmatory trials can take up to three years to complete. There is no indication as to when the Bedaquiline confirmatory trials will begin.

Due to the uncertainty, medical experts, including the president of the Southern African HIV Clinicians Society, Dr Francesca Conradie, and world-renowned epidemiologist Dr Quarraisha Abdool Karim wrote an open letter to Health Minister Aaron Motsoaledi and Medicines Control Council registrar Mandisa Hela urging them to expedite access to Bedaquiline through “compassionate use”.

Compassionate use is considered in cases where a patient has XDR-TB and the existing treatment options are failing to cure him.

Conradie and Abdool Karim, together with the Global Tuberculosis Community Advisory Board (TB CAB), argued that, “patients are dying because the current drug-resistant TB treatments are failing to cure XDR-TB except in a select few cases”.

XDR-TB is a potentially deadly and the most difficult TB strain to treat. It kills at least 40% of the people who are infected with it every year in the country.

In 2010, there were 741 recorded cases of the disease in South Africa.

This meant that about 297 of those patients died because the treatment was not effective.

Dr David Mametja, the health department’s chief director for TB control and management, acknowledged that limited XDR-TB treatment options meant that a high number of people died because of this infectious disease.

However, he said: “The MCC can not allow Bedaquiline to be used in an uncontrolled manner.”

“Bedaquiline has shown positive outcomes and we are all hoping that it would be the answer to drug-resistant TB but it is still under research. We are in discussion with the MCC to explore the possibility of compassionate use and even then the risks and benefits will have to be weighed,” Mametja said.

Dr Iqbal Master, a leading drug-resistant TB expert based at the King George V Hospital in Durban agreed with Mametja that all parties needed to be careful going forward.

But, he said: “While we wait for more trials to be conducted on the efficacy of Bedaquiline it would be good to offer it to some patients that meet the compassionate use criteria.”

Join the conversation! encourages commentary submitted via MyNews24. Contributions of 200 words or more will be considered for publication.

We reserve editorial discretion to decide what will be published.
Read our comments policy for guidelines on contributions. publishes all comments posted on articles provided that they adhere to our Comments Policy. Should you wish to report a comment for editorial review, please do so by clicking the 'Report Comment' button to the right of each comment.

Comment on this story
Comments have been closed for this article.

Inside News24

Traffic Alerts
There are new stories on the homepage. Click here to see them.


Create Profile

Creating your profile will enable you to submit photos and stories to get published on News24.

Please provide a username for your profile page:

This username must be unique, cannot be edited and will be used in the URL to your profile page across the entire network.


Location Settings

News24 allows you to edit the display of certain components based on a location. If you wish to personalise the page based on your preferences, please select a location for each component and click "Submit" in order for the changes to take affect.

Facebook Sign-In

Hi News addict,

Join the News24 Community to be involved in breaking the news.

Log in with Facebook to comment and personalise news, weather and listings.